MTOR and acute lymphoblastic leukemia: To better evaluate the effectiveness of PI3K/Akt/mTOR inhbitors as potential therapeutic agents in T-ALL, we examined 6 pediatric T-ALL patient samples, isolated from bone marrow or peripheral blood and characterized by constitutive activation of the pathway.